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Introduction {#sec1}
============

The seven-transmembrane-helix receptors (7TMRs) comprise a large and diverse family of cell-surface receptors that on agonist binding can bind and activate a G protein and subsequently initiate diverse signaling events. Some ligands also stimulate G protein-independent pathways ([@bib33]); unless otherwise stated, the terms "agonist" and "antagonist," etc. refer to the G protein-coupled pathway (see [Box 1](#tbox1){ref-type="boxed-text"} for pharmacological definitions). The 7TMRs are the largest single class of drug target ([@bib52]), and the β-adrenoceptors (βARs) are the targets of beta blockers (antagonists of the G protein-coupled pathway) in the treatment of heart failure, as well as agonists used in asthma therapies. Recent structures of both the β~1~-adrenoceptor (β~1~AR) and the β~2~-adrenoceptor (β~2~AR) have led to an understanding of the molecular characteristics that define an agonist compared to an inverse agonist and how an agonist promotes the activation of a G protein ([@bib6]; [@bib15]; [@bib29]; [@bib46]; [@bib48], [@bib50]). The structures of the inactive states (R) of βARs when bound to antagonists are very similar, although there are some differences in the region of the "ionic lock" depending on whether the salt bridge between Arg^3.50^ and Glu^6.30^ is present or not ([@bib29]) (superscripts refer to the Ballesteros Weinstein nomenclature ([@bib3])). When full agonists bind to the R state, the most significant effects are the contraction of the binding pocket and the change in rotamer conformation of Ser^5.46^, implying that these are a prerequisite to the attainment of the activated state (R^∗^) that can couple to G proteins ([@bib50]). In contrast to agonists, partial agonists apparently do not form a hydrogen bond to Ser^5.46^, which explains their decreased efficacy ([@bib50]). The structure of β~2~AR bound to either a G protein mimetic or Gs shows that the agonists bind to R^∗^ in the same manner as to the R state and that the intracellular regions of helices 5 and 6 move by 10-14 Å upon activation ([@bib38]; [@bib39]). The challenge over the coming years is to relate the structures of the βARs bound to various ligands and the pharmacological effects of drugs targeting βARs in humans, particularly where the ligands also stimulate G protein-independent pathways, such as through interactions with arrestin.

In the classical view of 7TMR-ligand interactions, agonists bind to receptors and stimulate the activity of specific G proteins to varying degrees, whereas inverse agonists block the effects of agonist activation and also inhibit constitutive signaling. In this view, sometimes termed linear efficacy, the signaling processes associated with a drug\'s activity are in proportion to its efficacy and therefore its position on the scale of effects ranging from that of a full to an inverse agonist of a G protein, as was shown in early studies on the β~2~AR ([@bib4]). It is now clear that this is an oversimplification, and the more recent concept of biased agonist function has evolved in response to a body of evidence that shows that 7TMRs can interact directly with other signaling partners, for example, arrestin. These alternative G protein-independent signaling pathways can be selectively stimulated alongside G protein activation, and a ligand\'s efficacy can be "biased" more or less to different pathways ([@bib36]; [@bib45]). In addition to the implied requirement for distinct conformational states to explain these receptor activities ([@bib16]), there is also a growing realization that existing drugs that target 7TMRs may have more complex effects than first realized, and that the concept of ligand bias may therefore allow the development of more effective therapies ([@bib51]).

Carvedilol and bucindolol are both beta blockers (antagonists) that target β~1~AR (see [Figure 1](#fig1){ref-type="fig"} for the structures of ligands) and can also bind to β~2~AR. However, both bucindolol and carvedilol have also been shown to stimulate non-G protein-coupled pathways of βARs (i.e., they are biased agonists). With the human β~1~AR, bucindolol has been found to act as a partial agonist of the G protein-signaling pathway as well as an agonist of the mitogen-activated protein kinase (MAPK) pathway through a G protein-independent mechanism ([@bib13]). This suggests that bucindolol can induce a signaling conformation of β~1~AR that is distinct from both conventional (G protein) antagonist-bound and agonist-bound states ([@bib13]). All conventional βAR agonists can enhance arrestin-mediated signaling as a functional consequence of their activation of the G protein-signaling pathway ([@bib9]; [@bib53]). However, carvedilol is an inverse agonist of G protein signaling, but it stimulates arrestin-mediated signaling pathways of both human β~2~AR and mouse β~1~AR independently of G protein-mediated signaling ([@bib17]; [@bib53]). Because of these unique properties, its interactions with βARs will be of interest as it has been suggested that carvedilol could be a prototype for the design of a new generation of therapeutic agents that could stimulate arrestin-dependent signaling, with potentially increased cardioprotective effects, to a greater extent than current beta blockers ([@bib31]; [@bib32]; [@bib53]).

The major structural changes that result in binding and activation of a G protein by a 7TMR include large outward movements of transmembrane helices 5 and 6 ([@bib39]), but the receptor conformational changes that might promote arrestin-mediated signaling or signaling through other G protein-independent pathways in preference to G protein activation are at present unknown. In the case of the β~2~AR, ligands that stimulate arrestin signaling are thought to cause conformational changes at the receptor\'s C terminus, and these might promote phosphorylation and facilitate interactions with regulatory proteins such as arrestin ([@bib14]). Small increases in phosphorylation levels of the β~2~AR C terminus have been demonstrated for some arrestin-biased agonists, including carvedilol ([@bib9]), and the resulting pattern of phosphorylation is distinct from that promoted in response to stimulation with the nonbiased agonist, isoprenaline ([@bib31]).

Bucindolol and carvedilol are clearly of interest in relation to their role in the activation of non-G protein-mediated signaling pathways, and, in addition, they are also being studied with respect to two isoforms of human β~1~AR in the treatment of congestive heart failure. A common single nucleotide polymorphism occurs in amphipathic helix 8 (H8) of human β~1~AR, where Arg389^8.56^ is substituted by Gly in 20%--40% of the population depending on ethnicity ([@bib26]). The Arg/Gly389 polymorphism results in a significant variation in G protein activation, with β~1~AR-Arg389 having a slightly higher basal activity and a 3-fold increased adenylyl cyclase activity on stimulation with the nonbiased agonist isoprenaline compared to β~1~AR-Gly389 ([@bib27]). Both carvedilol and bucindolol have been shown to be more effective than other beta blockers as inverse agonists of β~1~AR-Arg389 ([@bib22]; [@bib40]), findings which were initially heralded as a starting point for personalized therapies in heart failure ([@bib8]; [@bib35]).

In order to elucidate the interactions of these ligands with the receptor as a foundation for further studies of signaling with biased agonists, and to determine possible reasons for the enhanced activities of the ligands on β~1~AR-Arg389, we have determined the cocrystal structures of a thermostabilized avian β~1~AR with bucindolol and carvedilol.

Results and Discussion {#sec2}
======================

Structures of β~1~AR Bound to Bucindolol and Carvedilol {#sec2.1}
-------------------------------------------------------

The avian β~1~AR was modified to allow crystallization by the removal of flexible regions at the N terminus, C terminus, and in cytoplasmic loop 3, and the introduction of 8 point mutations (see [Experimental Procedures](#sec1){ref-type="sec"}), to give the construct β~1~AR44-m23. Six of the point mutations result in thermostabilization of β~1~AR ([@bib43]), which allows crystallization in short-chain detergents ([@bib48]). A consequence of thermostabilization is that the receptor is preferentially in the antagonist-bound state (R) ([@bib43]), although β~1~AR-m23 is capable of binding agonists with a similar rank order of potency to the wild-type receptor and can couple efficiently to G proteins ([@bib2]). It is not feasible to perform crystallography on human β~1~AR due to its extreme instability ([@bib42]), but the high sequence identity between the receptors (82%) in the transmembrane domains and loop regions (except most of cytoplasmic loop 3) shows β~1~AR-m23 is an excellent model for studying ligand-receptor interactions. Indeed, crystal structures of β~1~AR-m23 ([@bib48]) and β~2~AR-T4L ([@bib6]) show high similarity in the transmembrane domains (rmsd 0.7 Å) and especially in the region of the ligand binding pocket (rmsd of 0.25 Å for 78 Cα atoms). None of the mutations in β~1~AR-m23 are in the ligand binding pocket and none of the sites of the mutations show a conformational change when comparing the structures of β~1~AR-m23 and β~2~AR-T4L.

Receptors were expressed, purified and crystallized as previously described. The cocrystal structures of β~1~AR44-m23 bound to either bucindolol or carvedilol were solved at resolutions of 3.2 and 2.3 Å, respectively ([Figure 2](#fig2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). Overall the two structures are very similar (RMSD of Cα positions \<0.5 Å) to the inactive state structure of β~1~AR (Protein Data Bank \[PDB\] [2VT4](pdb:2VT4)) with bound cyanopindolol ([@bib48]). The lack of any significant conformational change at the ends of helices 5 and 6 is consistent with previous R-state structures of β~1~AR-m23 with bound antagonists and agonists and of β~2~AR complexed with either antagonists or with a covalently bound agonist. Thus, the structures presented here of β~1~AR bound to either bucindolol or carvedilol show in detail the ligand-receptor interactions (see below), but they do not define a new conformation of the receptor involved in G protein-independent signaling. It is likely that a complex of a phosphorylated βAR with arrestin will be required to fully understand the conformational change induced by the binding of biased agonists, because the signaling conformation of the receptor that allows arrestin binding is likely to be transient. This is consistent with the observation that the binding of a G protein or analog was required to obtain the structure of an R^∗^ state of β~2~AR ([@bib38], [@bib39]), while the structure of β~2~AR bound to a covalent agonist is in the R state ([@bib41]). Therefore, it seems unlikely that any key conformational changes are missing due to the presence of the thermostabilizing mutations. In contrast to the βARs, some receptors evince considerable conformational changes when crystallized in the presence of an agonist. For example, the structure of the adenosine A~2A~ receptor bound to an agonist is clearly in an R^∗^-like state, without the requirement for binding a G protein or G protein mimetic ([@bib20]; [@bib54]).

Ligand Binding in the Catecholamine Binding Pocket {#sec2.2}
--------------------------------------------------

The structures of βAR ligands are often very similar, particularly in the region of the secondary amine and β-hydroxyl groups and these are also conserved in bucindolol and carvedilol ([Figure 1](#fig1){ref-type="fig"}). The cocrystal structures show that their secondary amine and β-hydroxyl groups form potential hydrogen bonds with Asp121^3.32^ and Asn329^7.39^ and their "head groups" (equivalent to the catechol moiety in adrenaline) occupy a position adjacent to H5 ([Figure 3](#fig3){ref-type="fig"}). Thus, both ligands exhibit the same general mode of binding observed for other βAR antagonists cocrystallized with either β~1~AR or β~2~AR ([@bib6]; [@bib15]; [@bib29]; [@bib46]; [@bib48]).

Previously, we showed that binding of a full agonist to β~1~AR resulted in three differences in receptor conformation compared to when an antagonist was bound, namely the rotamer conformation changes of Ser212^5.43^ and Ser215^5.46^, and a contraction of the ligand binding pocket. Comparison of the structures of β~1~AR bound to bucindolol and carvedilol with the previously determined structures shows that the rotamer configuration of Ser215^5.46^ allows the formation of an interhelical hydrogen bond with H3, as seen in the structures with bound partial agonists, but not with bound full agonists where Ser215^5.46^ forms a hydrogen bond directly to the ligand ([Figure 4](#fig4){ref-type="fig"}). However, the configuration of Ser212^5.43^ is similar to that seen in the agonist-bound structures where it makes a potential hydrogen bond to Asn310^6.55^. A recently determined structure of β~1~AR with cyanopindolol bound in lipidic meso phase at a resolution of 2.1 Å (J.L. Miller and C.G.T., unpublished data) also shows this alternative rotamer conformation of Ser212^5.43^ compared to the previous structure of cyanopindolol-bound β~1~AR determined in detergent ([@bib48]); these data suggest that Ser212^5.43^ can also be in this alternative conformation with an antagonist bound, and the configuration of Ser212^5.43^ is therefore unlikely to represent an agonist-specific conformation. Both the bucindolol and carvedilol bound structures also do not exhibit the contraction of the binding pocket observed in the structures with full and partial agonists bound. It is therefore clear that the ligands do not induce the initial conformational changes in the receptor that are characteristic of agonists that activate G proteins. Bucindolol has been variously reported as being either an inverse agonist or partial agonist of the β~1~AR, depending on the system or tissue studied ([@bib1]; [@bib11]; [@bib13]; [@bib24; @bib25]). However, in both bucindolol-bound and carvedilol-bound β~1~AR structures, the characteristic rotamer conformation change of Ser215^5.46^ observed in structures with a full agonist bound is sterically blocked by the ligand, which is a characteristic of βAR inverse agonists ([@bib50]).

Ligand Binding in the Extended Ligand Binding Pocket {#sec2.3}
----------------------------------------------------

Both bucindolol and carvedilol, unlike all other antagonists cocrystallized with βARs, have bulky aromatic substituents at their amine ends that make additional contacts in the extended ligand binding pocket composed of residues in helices 2, 3, and 7 and extracellular loop 2 ([Figure 4](#fig4){ref-type="fig"}). The additional contacts are detailed along with all other ligand-receptor contacts in [Table 2](#tbl2){ref-type="table"}. It therefore seems logical to propose that the ability of bucindolol and carvedilol to stimulate G protein-independent signaling resides in the extensions in the tail region of the ligand that are absent from all other antagonists. However, it is difficult to say how these additional contacts might promote G protein-independent signaling, because the conformations that might finally promote the binding of arrestin or other signaling proteins are currently unknown. However, it seems plausible that the additional contacts may result in an increased probability of subtle conformational changes that might be transmitted to the receptor\'s C terminus, where phosphorylation by GPCR-specific kinases promotes binding of arrestin and signaling ([@bib14]; [@bib31]).

Bias of conventional G protein agonists of βARs toward the arrestin-signaling pathway has been investigated and methods to discern levels of G protein-independent activity that are relatively low compared to the dominant G protein-signaling activity are being developed. This has led to the categorization of a number of ligands that can activate both G protein-coupled and G protein-independent pathways, but to different extents ([@bib37]). However, currently there is not a comprehensive list of the propensity of all βAR ligands for inducing signaling via G protein-independent pathways. So far, bias toward arrestin signaling among conventional G protein agonists has only been detected in ligands with either ethyl substitutions at the Cα, or amine-end substituents, such as those present in bucindolol and carvedilol ([@bib9]; [@bib37]). Of the conventional G protein agonists that have been cocrystallized previously with either β~1~AR or β~2~AR, dobutamine, isoprenaline and salbutamol have been identified as nonbiased agonists of the β~2~AR ([@bib37]). The structure of β~1~AR bound to carmoterol has been determined ([@bib50]), but this ligand has not been tested for signaling bias. However, formoterol, which is weakly arrestin biased, is structurally identical to carmoterol apart from a minor difference in its head group; both ligands have the same methoxyphenyl amine end extension (see [Figure 1](#fig1){ref-type="fig"} for the structures) ([@bib36]). The cocrystal structure of carmoterol with the β~1~AR indicates additional interactions of the methoxyphenyl group with extracellular loop 2 (EL2) as well as H7, and NMR data suggest that formoterol\'s methoxyphenyl group also interacts with residues on EL2 of the β~2~AR ([@bib5]). Thus, of the three ligands with amine-end extensions that bind in the extended ligand binding pocket for which there are cocrystal structures and that have been examined for bias, bucindolol and carvedilol are biased agonists, whereas dobutamine is not. As in all probability, formoterol, which also shows weak arrestin bias also binds to EL2, one structural feature that may correlate with agonist bias is that bucindolol, carvedilol, and most likely formoterol all interact with EL2, whereas dobutamine does not. Whether this observation extends to other biased agonists will require further detailed characterization of more βAR ligands with both β~1~AR and β~2~AR rather than just a limited few.

While this manuscript was in review, a related manuscript appeared ([@bib23]), which detailed ^19^F-NMR studies on β~2~AR bound to various ligands. Specific Cys residues in detergent-solubilized, purified β~2~AR were covalently modified with trifluoroethanethiol and then ^19^F spectra were collected in the presence of inverse agonists, agonists, or biased agonists. The most significant difference observed when an inverse agonist was bound compared to when a biased agonist was bound was a change in the spectrum of ^19^F-labeled Cys327; this residue is in the short linker between H7 and H8. These data indicate that the environment around Cys327 is different when a biased agonist is bound compared to when an inverse agonist is bound, which is consistent with the interpretation of the structural data presented here and previous biochemical data ([@bib14]; [@bib31]).

Understanding the Effects of the Arg389Gly Polymorphism in Human β~1~AR {#sec2.4}
-----------------------------------------------------------------------

The high-resolution of the β~1~AR-carvedilol complex fortuitously also allows us to suggest a mechanism for the difference in pharmacology in the frequently occurring Arg389Gly polymorphism of the human β~1~AR. The more common β~1~AR-Arg389 variant has a slightly higher basal G protein activity and a 3-fold increase in agonist response compared to the β~1~AR-Gly389 variant ([@bib27]). It has been suggested that the affected residue is in an area important for G protein coupling ([@bib27]), but it is now clear from the structure of the β~2~AR-Gs complex that this is not the case ([@bib39]). Therefore, the differences in pharmacology between the Arg/Gly variants must lie within the receptor itself.

The human β~1~AR residue affected by the polymorphism, Arg389^8.56^, is equivalent to Arg355^8.56^ in the turkey β~1~AR and it is located on H8, with its guanidinium group close to the end of H7. In the 2.3 Å resolution structure of carvedilol-bound β~1~AR-m23, the side chain of Arg355^8.56^ is well resolved for the first time in any structure ([Figure 5](#fig5){ref-type="fig"}) and it forms hydrogen bonds with Ser68^1.59^ and Thr69^1.60^ at the intracellular end of H1. The hydrogen bonds between H8 and H1 would be expected to stabilize the receptor, which is substantiated by the fact that Ser68^1.59^ is one of the six thermostabilizing mutations that facilitated crystallization of β~1~AR-m23 ([@bib43]; [@bib42]). In the wild-type turkey β~1~AR, the equivalent residue to Ser68^1.59^ is Arg68^1.59^ and when this is mutated to an uncharged residue (Ala) the receptor becomes more thermostable, presumably because the proximity of Arg68^1.59^ and Arg355^8.56^ is electrostatically unfavorable. Mutation of Arg68^1.59^ to Ser increases the thermostability further, which is consistent with the formation of the hydrogen bond to Arg355^8.56^ observed in the structure with bound carvedilol. Increased thermostability of β~1~AR is likely to reflect a decrease in the global flexibility of the whole receptor. Thus, changes in thermostability due to mutations at the H1-H8 interface suggests that analogous changes in homologous receptors may also change the global dynamics of these receptors. These observations in the avian β~1~AR probably apply to human β~1~AR and β~2~AR as the equivalent residues to Arg68^1.59^ are Lys85^1.59^ and Lys60^1.59^. Thus, the Arg/Gly389 polymorphism in human β~1~AR will similarly alter the packing between H1 and H8, which could result in changes in the dynamics of the receptor, with the barrier to formation of the R^∗^ state perhaps being lower in the β~1~AR-Arg389 variant. This is indeed what has been observed pharmacologically and biochemically in a number of studies ([@bib22]; [@bib40]; [@bib44]). It has also been observed that carvedilol is a more efficient inverse agonist of the human β~1~AR-Arg389 isoform than are metoprolol and bisoprolol ([@bib40]), two beta blockers that do not have extensions at their amine ends (see [Figure 1](#fig1){ref-type="fig"}). These findings have led to interest in the potential of genetically targeted therapies for heart failure with bucindolol or carvedilol ([@bib8]; [@bib35]). A similar polymorphism at Trp64^1.59^ in the human β~3~AR has also been observed, where substitution of Trp for Arg has been associated with compromised activity of the receptor and, consequently, increased obesity ([@bib18]; [@bib19]; [@bib34]).

Conclusions {#sec2.5}
-----------

The structures of β~1~AR bound to either bucindolol or carvedilol show that both of these ligands make additional contacts to helices 2, 3, and 7 and extracellular loop 2 compared to other structurally characterized βAR inverse agonists. Overall the structures show no conformational change when compared to other β~1~AR antagonist structures, but it is probable that the additional interactions in the extended ligand binding pocket might increase the likelihood of subtle conformational changes that result in enhanced arrestin binding and G protein-independent signaling. The fact that both bucindolol and carvedilol bind to β~1~AR in a similar manner to other βAR G protein antagonists, yet they can stimulate signaling via G protein-independent pathways while apparently inhibiting G protein coupling, strongly supports the contention that arrestin can bind to a different conformation of the receptor to that bound by G proteins.

Experimental Procedures {#sec3}
=======================

Expression, Purification, and Crystallization {#sec3.1}
---------------------------------------------

The turkey (*Meleagris gallopavo*) β~1~AR construct, β44-m23, contains six thermostabilizing point mutations, two point mutations which improve receptor expression and homogeneity, and truncations at the N terminus, inner loop 3 and C terminus ([@bib50]). Baculovirus expression and purification were all performed as described previously, with the detergent exchanged to Hega-10 (0.35%) on the alprenolol Sepharose affinity column ([@bib47], [@bib48], [@bib49], [@bib50]). Purified receptor was competitively eluted from the alprenolol Sepharose column with either bucindolol or carvedilol, but this was difficult because of the poor solubility of the ligands. Ligands were added to saturation from 20 mg/ml DMSO stock solutions to the elution buffer (10 mM Tris-HCl \[pH 7.4\], 100 mM NaCl, 0.1 mM EDTA, 0.35% Hega-10) with rapid stirring. The approximate final concentrations of the ligands in the elution buffer were 10 μM for carvedilol and 50 μM for bucindolol. Receptor was concentrated to 20 mg/ml in 10 mM Tris-HCl (pH 7.6), 100 mM NaCl, 0.1 mM EDTA, 0.35% Hega-10. Before crystallization, Hega-10 was added to 0.5%. Crystals were grown at 4°C by vapor diffusion in sitting drops with 150 nl receptor + 150 nl precipitant (0.1 M bicine \[pH 9.0\], 25% PEG 600 in both cases) and cryoprotected by addition of 60% PEG 600 for 1 min before mounting on Hampton CrystalCap HT loops and cryocooling in liquid nitrogen.

Data Collection, Structure Solution, and Refinement {#sec3.2}
---------------------------------------------------

For both complexes, diffraction data were collected from a single cryocooled crystal (100 K) at the European Synchrotron Radiation Facility, Grenoble, France, with a Mar 225 CCD detector on beamline ID23-2 (wavelength, 0.8726 Å) using a 10 μm focused beam. The microfocus beam was required for the location of the best diffracting parts of crystals, as well as allowing wedges of data (20--80°) to be collected from different positions on the crystal. For the β~1~AR crystals grown in the presence of bucindolol or carvedilol, 9 or 16 wedges of data from single crystals were merged, respectively. Images were processed with MOSFLM ([@bib21]) and SCALA ([@bib12]). Both structures were solved by molecular replacement with PHASER using the β~1~AR44-m23 structure with the agonist carmoterol bound (PDB code [2Y02](pdb:2Y02)) as a starting model ([@bib28]). Refinement, rebuilding and validation were carried out with REFMAC5 ([@bib30]), COOT ([@bib10]) and MOLPROBITY ([@bib7]). Noncrystallographic symmetry restraints were applied as appropriate between the two monomers in the asymmetric unit for both structures, using the electron density maps and R~free~ values to judge which residues should be excluded. The two independent copies of the receptor in the asymmetric unit are very similar for the bucindolol complex, although the ligand density was better defined for monomer A. In the carvedilol complex, there is a distortion of the ligand binding pocket in monomer A due to lattice contacts and monomer B represents the more physiologically relevant conformation.

Accession Numbers {#app1}
=================

Coordinates and structure factors have been submitted to the PDB database under accession codes [4AMI](pdb:4AMI) and [4AMJ](pdb:4AMJ) for b44-m23 bound to either bucindolol or carvedilol, respectively.
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![Structures of βAR Ligands Discussed in the Main Text\
Highlighted regions of the ligands are either conserved with the agonist adrenaline (blue) or are conserved among antagonists (red).](gr1){#fig1}

![Structure of β~1~-Adrenoceptor bound to Carvedilol\
(A) The structure of β1AR bound to carvedilol, with the receptor monomer in rainbow coloration with the N terminus in blue and the C terminus in red. Carvedilol is shown in space-filling representation (C, gray; O, red; N, blue). The intracellular side is at the bottom of the figure.\
(B) Omit map (2Fo-Fc) density for carvedilol (contour level 1.3 σ).\
(C) Omit map (2Fo-Fc) density for bucindolol (contour level 1.0 σ).\
(D--F) Alignment of β1AR structures was performed and the superposition of the ligands are depicted. (D) Alignment of bucindolol (pink) and cyanopindolol (gray, PDB code [2VT4](pdb:2VT4)). (E) Alignment of bucindolol (pink) with carvedilol (green). (F) Alignment of carvedilol (green) with carazolol (yellow, PDB code [2YCW](pdb:2YCW)).](gr2){#fig2}

![Structures of the Ligand Binding Pocket\
β~1~AR-m23 is depicted as a cartoon (gray) viewed from the extracellular surface with specific side chains (C, green; N, red; O, blue) depicted making potential hydrogen bonds (red dashed lines) to the ligand, as well as the interhelical potential hydrogen bond between Ser212^5.43^ and Asn310^6.55^. The ligand coloring scheme is C, yellow; N, red; O, blue.\
(A) Bucindolol.\
(B) Carvedilol. Note the alternative rotamer conformation of Asn310^6.55^ depicted in the carvedilol-bound structure in which the amide oxygen faces toward H5. In this configuration a potential steric clash with the ligand is avoided, this conformation could be dependent on the nature of the ligand.](gr3){#fig3}

![Key Receptor-Ligand Interactions between Bucindolol, Carvedilol, and β~1~AR\
Receptor structures are shown in cartoon representation as viewed in the membrane plane with the three helices obscuring the binding site removed for clarity and the remaining helices labeled: (A and B) monomer A of the bucindolol complex; (C and D) monomer B of the carvedilol complex. Amino acid residues within 3.9 Å of the ligands (yellow) are depicted in stick representation; green, residues with previously known ligand interactions; orange, residues in the extended ligand binding pocket interacting with either the indole or methoxyphenoxy substituents on the ligands. Atoms are colored accordingly; C, yellow, green, orange; O, red; N, blue. Potential hydrogen bonds are shown as red dashes. Carvedilol makes a polar contact with EL2 mediated by a bridging water molecule (red sphere labeled w; B-factor 42 Å^2^). The disulphide bond (labeled S-S) between Cys199 on EL2 and Cys114^3.25^ on H3 is shown in (B) and (D). For a full list of receptor-ligand interactions and Ballesteros-Weinstein nomenclature, see [Table 2](#tbl2){ref-type="table"}.](gr4){#fig4}

![Interactions between Amphipathic H8 and H1\
(A) The structure of carvedilol-bound β~1~AR-m23 is shown as viewed from the cytoplasmic surface in rainbow coloration (N terminus blue, C terminus red) and the helices labeled accordingly (H1-H8).\
(B) Region depicting the potential hydrogen bonds (red dashed lines) between side chains in H1 and H8. The electron density for Arg355 suggests that alternative rotamer conformations are present, but the conformation depicted represents the most favored.](gr5){#fig5}

###### 

Data Processing, Refinement, and Evaluation Statistics

                                                                    β44-m23 + Bucindolol       β44-m23 + Carvedilol
  ----------------------------------------------------------------- -------------------------- --------------------------
  Cell dimensions *a, b, c* (Å), β (^o^)                            89.8, 60.7, 107.8, 110.8   90.1, 62.2, 100.9, 109.2
                                                                                               
  **Data Processing**                                                                          
                                                                                               
  Resolution (Å)                                                    52.1--3.2                  52.1--2.3
  Rmerge[a](#tblfn1){ref-type="table-fn"}                           0.102 (0.596)              0.099 (0.593)
  \<I/σ(I)\>[a](#tblfn1){ref-type="table-fn"}                       9.9 (2.5)                  11.3 (2.1)
  Completeness (%)[a](#tblfn1){ref-type="table-fn"}                 95.9 (86.5)                99.8 (99.1)
  Multiplicity[a](#tblfn1){ref-type="table-fn"}                     5.3 (5.4)                  6.2 (4.0)
  Wilson B factor (Å^2^)                                            103.6                      37.5
                                                                                               
  **Refinement**                                                                               
                                                                                               
  Total number of reflections                                       16,557                     44,731
  Total number of atoms                                             4,673                      4,962
  Number of waters                                                  13                         100
  Number of detergent molecules                                     5                          12
  Number of sodium ions                                             0                          2
  R~work~[b,c](#tblfn2 tblfn3){ref-type="table-fn"}                 0.242 (0.350)              0.202 (0.288)
  R~free~[c,d](#tblfn3 tblfn4){ref-type="table-fn"}                 0.279 (0.384)              0.240 (0.315)
  Rmsd bonds (Å)                                                    0.005                      0.012
  Rmsd angles (^o^)                                                 0.984                      1.39
  Mean atomic B factor (Å^2^)                                       92.7                       39.2
  Estimated coordinate error (Å)                                    0.35                       0.125
  Ramachandran plot favored (%)[e](#tblfn5){ref-type="table-fn"}    98.2                       98.1
  Ramachandran plot outliers (%)[e](#tblfn5){ref-type="table-fn"}   0                          0

Values in parentheses are for the highest resolution bin (Å) (bucindolol, 3.37--3.2; carvedilol, 2.42--2.30).

Number of reflections used to calculate R~work~ (bucindolol, 15,659 \[94.9%\]; carvedilol, 42,352 \[95.0%\]).

Values in parentheses are for the highest resolution bin for refinement (Å) (bucindolol, 3.28--3.20; carvedilol, 2.36--2.30).

Number of reflections from a randomly selected subset used to calculate R~free~ (bucindolol, 898 \[5.1%\]; carvedilol 2,378 \[5.0%\]).

Figures obtained using MolProbity ([@bib7]).

###### 

Amino Acid Side-Chain Contacts between β~1~AR and Ligands

  Amino Acid Residue   B-W Number   Secondary Structure   Bucindolol Monomer A   Carvedilol Monomer B         Carazolol 2YCW Monomer A   Cyanopindolol 2VT4 Monomer B
  -------------------- ------------ --------------------- ---------------------- ---------------------------- -------------------------- ------------------------------
  Leu101               2.64         H2                    ---                    v der W                      ---                        ---
  Trp117               3.28         H3                    v der W                v der W                      v der W                    v der W
  Thr118               3.29         H3                    v der W                ---                          ---                        v der W
  Asp121               3.32         H3                    H-bond                 H-bond                       H-bond                     H-bond
  Val122               3.33         H3                    v der W                v der W                      v der W                    v der W
  Val125               3.36         H3                    v der W                v der W                      v der W                    ---
  Cys199               ---          EL2                   H-bond                 ---                          ---                        ---
  Asp200               ---          EL2                   v der W                v der W                      ---                        ---
  Phe201               ---          EL2                   v der W                v der W (H-bond via water)   v der W                    v der W
  Thr203               ---          EL2                   ---                    ---                          ---                        Polar
  Tyr207               5.38         H5                    ---                    v der W                      v der W                    ---
  Ala208               5.39         H5                    ---                    ---                          ---                        v der W
  Ser211               5.42         H5                    v der W                H-bond                       H-bond                     H-bond
  Ser215               5.46         H5                    v der W                v der W                      v der W                    v der W
  Trp303               6.48         H6                    v der W                v der W                      v der W                    v der W
  Phe306               6.51         H6                    v der W                v der W                      v der W                    v der W
  Phe307               6.52         H6                    v der W                v der W                      v der W                    v der W
  Asn310               6.55         H6                    v der W                v der W                      v der W                    H-bond
  Phe325               7.35         H7                    v der W                ---                          ---                        ---
  Val326               7.36         H7                    v der W                ---                          ---                        ---
  Asn329               7.39         H7                    H-bond                 H-bond                       H-bond                     H-bond
  Trp330               7.40         H7                    ---                    v der W                      ---                        ---
  Tyr333               7.43         H7                    v der W                v der W                      v der W                    v der W

###### Pharmacological Definitions

**Agonist.** A ligand that binds to and activates a receptor and elicits a physiological response. The endogenous agonist for the β~1~AR is noradrenaline, which is a full agonist that elicits the maximal response for the receptor in activating a G protein.

**Constitutive or basal activity.** Physiological response that occurs in the absence of any receptor-activating ligand due to a fraction of the receptor being in an activating conformation.

**Inverse agonist.** A ligand that binds to a receptor and inhibits or eliminates, in the case of a full inverse agonist, the basal or constitutive activity of a receptor.

**Partial agonist or partial inverse agonist.** Ligands that elicit only a partial response when compared to either a full agonist or a full inverse agonist, respectively.

**Antagonist.** Any ligand that blocks binding of endogenous agonists to the receptor, thereby modulating receptor activity. A general term that encompasses ligands that may be inverse agonists, partial agonists, or neutral in effect.

**Beta blockers.** Term for antagonists of βARs when used in a therapeutic setting.

**Biased agonist.** A ligand that binds to a receptor and signals to a variable extent through both G protein-dependent and G protein-independent pathways. A ligand may be "weakly biased," i.e., signaling is mainly via G proteins or "perfectly biased," i.e., the ligand is an inverse agonist of the G protein-coupled pathway as well as an agonist of the G protein-independent pathways.

**Note.** The categorization of ligands can be dependent on the type of assay used, the cell type in which the receptor has been expressed, expression levels, and the sensitivity and dynamic range of the assay used to detect downstream signaling events.
